基线前列腺特异性抗原低于3 ng/ml男性的前列腺癌死亡长期风险:芬兰前列腺癌筛查随机研究证据
该回顾性队列研究纳入芬兰前列腺癌筛查随机研究筛查组中初始PSA低于3 ng/ml的20268名男性,随访至多20年。中位随访17.8年期间诊断1840例前列腺癌、128例前列腺癌死亡,累积死亡率为0.6%,死亡率为每万人年4例。PSA 2-2.99 ng/ml组前列腺癌死亡风险是低于1 ng/ml组的5倍(HR 5.0,95%CI 3.1-8.1)。
要点
- 初始PSA低于3 ng/ml男性中位随访17.8年,前列腺癌累积死亡率为0.6%。
- PSA 2-2.99 ng/ml组前列腺癌死亡风险是低于1 ng/ml组的5倍(HR 5.0,95%CI 3.1-8.1)。
- 作者认为低PSA水平时联合其他检测可能有帮助,67-71岁PSA低时可停止筛查。
核心结论
- 研究结果强调前列腺癌筛查中需细致解读PSA,提示低水平时联合其他检测可能有帮助,并表明67-71岁且PSA低时停止筛查风险极小。
研究设计与样本
- 回顾性队列研究,纳入芬兰前列腺癌筛查随机研究筛查组中初始PSA低于3 ng/ml的20268名男性,随访至多20年。
主要发现
- 中位随访17.8年期间诊断1840例前列腺癌、发生128例前列腺癌死亡,累积前列腺癌死亡率为0.6%,死亡率为每万人年4例。
- PSA 2-2.99 ng/ml组前列腺癌死亡风险是低于1 ng/ml组的5倍(HR 5.0,95%CI 3.1-8.1)。
- Gleason评分低于7和欧洲泌尿外科学会低危组肿瘤的死亡与PSA关联更强,尤其在2-2.99 ng/ml组对比低于1 ng/ml组。
- 年轻男性(入组时55-58岁)前列腺癌死亡与PSA的关联强于老年男性(基线67-71岁)。
- 在基于Harrell C统计量的前列腺癌死亡总体预测中加入累积PSA检测次数略有改善(基础模型0.683 vs 0.717)。
临床怎么用
- 作者认为,在前列腺癌筛查中对PSA需采用细致的方法,低水平时联合其他检测可能有帮助。
- 作者指出,67-71岁且PSA低时停止筛查风险极小。
局限性
- 死亡数量相对较少,尤其在低危疾病男性中,可能限制结果的统计精确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Despite the evidence for prostate-specific antigen (PSA) screening reducing prostate cancer (PCa) mortality, the optimal PSA cutoff and the clinical significance of low initial PSA levels in predicting long-term PCa mortality remain subjects of ongoing research. We assessed PCa mortality among men with initial PSA levels below 3 ng/ml during the first screening round of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). METHODS: A retrospective cohort study was conducted, including 20 268 men from the screening arm of the FinRSPC with an initial PSA level of <3 ng/ml, with follow-up spanning up to 20 yr. Hazard ratios (HRs) and their 95% corresponding confidence intervals (CIs) were estimated using a Cox regression analysis. KEY FINDINGS AND LIMITATIONS: During a median follow-up of 17.8 yr, 1840 PCa cases were diagnosed and 128 PCa deaths occurred, with the cumulative PCa mortality of 0.6% and a mortality rate of four per 10 000 person-years. PCa mortality was five-fold higher at PSA levels of 2-2.99 ng/ml (HR 5.0, 95% CI 3.1-8.1) than at <1 ng/ml. Deaths from cases with Gleason score <7 and European Association of Urology low-risk group tumors showed a stronger association with PSA, particularly in the 2-2.99 ng/ml range versus <1 ng/ml. Additionally, PCa mortality in younger men (55-58 yr at entry) exhibited a stronger association with PSA than that in older men (67-71 yr at baseline). Addition of the cumulative number of PSA tests slightly improved the overall prediction of PCa death based on Harrell's C-statistic (base model 0.683 vs 0.717). The relatively small number of deaths, particularly among men with low-risk disease, may potentially limit the statistical precision of the results. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings highlight the importance of a nuanced approach to PSA in PCa screening, suggesting utility for combining PSA with other tests at low levels and indicating minimal risk associated with discontinuing screening at ages 67-71 yr when PSA is low. PATIENT SUMMARY: In this study, we analyzed prostate cancer deaths in Finnish men with low initial prostate-specific antigen (PSA) levels. We found that the risk of prostate cancer death increases in relation to PSA, especially in younger men. Screening might safely be stopped at ages 67-71 yr if PSA remains low.
引用
- Ola IO, Talala K, Tammela T, et al. Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Oncol. 2024. PMID: 39643505. doi:10.1016/j.euo.2024.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。